BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maréchal R, Demols A, Gay F, De Maertelaere V, Arvanitaki M, Hendlisz A, Van Laethem J. Prognostic Factors and Prognostic Index for Chemonaïve and Gemcitabine-Refractory Patients with Advanced Pancreatic Cancer. Oncology 2007;73:41-51. [DOI: 10.1159/000120627] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Jo JH, Chung MJ, Park JY, Bang S, Park SW, Chung JB, Song SY. Clinical Characteristics of Long-Term Survivors of Inoperable Pancreatic Cancer: An 8-Year Cohort Analysis in Korea. Pancreas 2014;43:1022-31. [DOI: 10.1097/mpa.0000000000000163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lou X, Li J, Wei YQ, Jiang ZJ, Chen M, Sun JJ. Comparable prevalence of distant metastasis and survival of different primary site for LN + pancreatic tumor. J Transl Med 2020;18:266. [PMID: 32611358 DOI: 10.1186/s12967-020-02438-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Nishiofuku H, Tanaka T, Marugami N, Sho M, Akahori T, Nakajima Y, Kichikawa K. Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. Eur Radiol 2016;26:1835-42. [PMID: 26385808 DOI: 10.1007/s00330-015-3999-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
5 Le N, Sund M, Vinci A; GEMS collaborating group of Pancreas 2000. Prognostic and predictive markers in pancreatic adenocarcinoma. Dig Liver Dis 2016;48:223-30. [PMID: 26769569 DOI: 10.1016/j.dld.2015.11.001] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 9.7] [Reference Citation Analysis]
6 Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Cancer Rep (Hoboken) 2020;3:e1215. [PMID: 32672000 DOI: 10.1002/cnr2.1215] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Hsu CC, Liu KH, Chang PH, Chen PT, Hung CY, Hsueh SW, Yeh KY, Chen YY, Lu CH, Hung YS, Chou WC. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy. J Gastroenterol Hepatol 2020;35:1694-703. [PMID: 31711261 DOI: 10.1111/jgh.14926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Nakai Y, Isayama H, Sasaki T, Sasahira N, Kogure H, Hirano K, Tsujino T, Ijichi H, Tateishi K, Tada M. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol. 2010;40:774-780. [PMID: 20462979 DOI: 10.1093/jjco/hyq059] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
9 Tsavaris N, Kavantzas N, Tsigritis K, Xynos ID, Papadoniou N, Lazaris A, Kosmas C, Agrogiannis G, Dokou A, Felekouras E, Antoniou E, Polyzos A, Sarantonis J, Tsipras H, Karatzas G, Papalambros A, Patsouris ES. Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. BMC Cancer 2009;9:264. [PMID: 19646258 DOI: 10.1186/1471-2407-9-264] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
10 Wilcox CM, Kim H, Seay T, Varadarajulu S. Choice of plastic or metal stent for patients with jaundice with pancreaticobiliary malignancy using simple clinical tools: a prospective evaluation. BMJ Open Gastroenterol 2015;2:e000014. [PMID: 26462270 DOI: 10.1136/bmjgast-2014-000014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Aslani A, Gill AJ, Roach PJ, Allen BJ, Smith RC. Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's procedure. HPB (Oxford) 2010;12:325-33. [PMID: 20590908 DOI: 10.1111/j.1477-2574.2010.00171.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
12 Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers (Basel). 2019;11. [PMID: 30965637 DOI: 10.3390/cancers11040497] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
13 Orman ES, Ghabril M, Chalasani N. Poor Performance Status Is Associated With Increased Mortality in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2016;14:1189-1195.e1. [PMID: 27046483 DOI: 10.1016/j.cgh.2016.03.036] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
14 Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, Mansmann U, Heinemann V, Boeck S. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol. 2010;31:351-357. [PMID: 20480409 DOI: 10.1007/s13277-010-0044-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
15 Custodio A, Puente J, Sastre J, Díaz-Rubio E. Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions. Cancer Treat Rev. 2009;35:676-684. [PMID: 19758760 DOI: 10.1016/j.ctrv.2009.08.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
16 Péus D, Newcomb N, Hofer S. Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak 2013;13:72. [PMID: 23870327 DOI: 10.1186/1472-6947-13-72] [Cited by in Crossref: 126] [Cited by in F6Publishing: 100] [Article Influence: 14.0] [Reference Citation Analysis]
17 Ling Q, Xu X, Zheng SS, Kalthoff H. The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models. Hepatobiliary Pancreat Dis Int 2013;12:480-7. [PMID: 24103277 DOI: 10.1016/s1499-3872(13)60076-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
18 Thuluvath PJ, Thuluvath AJ, Savva Y. Karnofsky performance status before and after liver transplantation predicts graft and patient survival. Journal of Hepatology 2018;69:818-25. [DOI: 10.1016/j.jhep.2018.05.025] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
19 Gebauer L, Moltz JH, Mühlberg A, Holch JW, Huber T, Enke J, Jäger N, Haas M, Kruger S, Boeck S, Sühling M, Katzmann A, Hahn H, Kunz WG, Heinemann V, Nörenberg D, Maurus S. Quantitative Imaging Biomarkers of the Whole Liver Tumor Burden Improve Survival Prediction in Metastatic Pancreatic Cancer. Cancers (Basel) 2021;13:5732. [PMID: 34830885 DOI: 10.3390/cancers13225732] [Reference Citation Analysis]
20 Chang CF, Huang PW, Chen JS, Chen YY, Lu CH, Chang PH, Hung YS, Chou WC. Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic Model. Cancers (Basel) 2019;11:E57. [PMID: 30634387 DOI: 10.3390/cancers11010057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
21 Wild AT, Ye X, Ellsworth SG, Smith JA, Narang AK, Garg T, Campian J, Laheru DA, Zheng L, Wolfgang CL, Tran PT, Grossman SA, Herman JM. The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol 2015;38:259-65. [PMID: 23648440 DOI: 10.1097/COC.0b013e3182940ff9] [Cited by in Crossref: 99] [Cited by in F6Publishing: 65] [Article Influence: 14.1] [Reference Citation Analysis]
22 Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, Kim JS, Kim YH. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy. Clin Oncol (R Coll Radiol) 2012;24:105-11. [PMID: 21382702 DOI: 10.1016/j.clon.2011.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
23 Takahara N, Isayama H, Nakai Y, Sasaki T, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Yamamoto N. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Cancer Chemother Pharmacol. 2013;72:985-990. [PMID: 23995699 DOI: 10.1007/s00280-013-2278-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
24 Hayashi H, Kohno T, Ueno H, Hiraoka N, Kondo S, Saito M, Shimada Y, Ichikawa H, Kato M, Shibata T, Morizane C, Sakamoto Y, Shimada K, Komatsu Y, Sakamoto N, Okusaka T. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer. Pancreas 2017;46:335-40. [DOI: 10.1097/mpa.0000000000000760] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
25 Lim KH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. Cancer Chemother Pharmacol 2011;68:1017-26. [PMID: 21327930 DOI: 10.1007/s00280-011-1584-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
26 Rezai P, Yaghmai V, Tochetto SM, Galizia MS, Miller FH, Mulcahy MF, Small W. Change in the Growth Rate of Localized Pancreatic Adenocarcinoma in Response to Gemcitabine, Bevacizumab, and Radiation Therapy on MDCT. International Journal of Radiation Oncology*Biology*Physics 2011;81:452-9. [DOI: 10.1016/j.ijrobp.2010.05.060] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
27 İnal A, Kos FT, Algın E, Yıldız R, Berk V, Unek İT, Colak D, Dane F, Geredeli C, Isıkdogan A. Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology). Contemp Oncol (Pozn) 2015;19:125-9. [PMID: 26034390 DOI: 10.5114/wo.2014.43933] [Reference Citation Analysis]
28 Kurihara T, Kogo M, Ishii M, Shimada K, Yoneyama K, Kitamura K, Shimizu S, Yoshida H, Kiuchi Y. Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol 2015;76:1217-24. [PMID: 26560484 DOI: 10.1007/s00280-015-2887-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
29 Hang J, Wu L, Zhu L, Sun Z, Wang G, Pan J, Zheng S, Xu K, Du J, Jiang H. Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real-world study. Cancer Med 2018. [PMID: 29856121 DOI: 10.1002/cam4.1573] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
30 Sena GR, Lima TPF, Mello MJG, Thuler LCS, Lima JTO. Developing Machine Learning Algorithms for the Prediction of Early Death in Elderly Cancer Patients: Usability Study. JMIR Cancer 2019;5:e12163. [PMID: 31573896 DOI: 10.2196/12163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
31 Thuluvath PJ, Thuluvath AJ, Savva Y, Zhang T. Karnofsky Performance Status Following Liver Transplantation in Patients With Multiple Organ Failures and Probable Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology 2020;18:234-41. [DOI: 10.1016/j.cgh.2019.03.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
32 Iede K, Yamada T, Kato R, Ueda M, Tsuda Y, Nakashima S, Ohta K, Matsuyama J, Ikenaga M, Tominaga S. Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer. Cancer Rep (Hoboken) 2020;3:e1289. [PMID: 32969199 DOI: 10.1002/cnr2.1289] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Xue P, Zhu L, Wan Z, Huang W, Li N, Chen D, Hu J, Yang H, Wang L. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. J Cancer Res Clin Oncol 2015;141:1653-60. [PMID: 25792009 DOI: 10.1007/s00432-015-1953-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
34 Lee JE, Lee HS, Chung MJ, Park JY, Park SW, Song SY, Bang S. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer. Gut Liver 2020;14:135-43. [PMID: 30974927 DOI: 10.5009/gnl18419] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Haas M, Laubender RP, Klose C, Schulz C, Mansmann U, Boeck S, Heinemann V. External validation of 2 prognostic indices for patients with advanced pancreatic cancer treated with first-line therapy. Pancreas 2012;41:738-44. [PMID: 22286380 DOI: 10.1097/MPA.0b013e31823bcc7b] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Keim V, Klar E, Poll M, Schoenberg MH. Postoperative care following pancreatic surgery: surveillance and treatment. Dtsch Arztebl Int. 2009;106:789-794. [PMID: 20038981 DOI: 10.3238/arztebl.2009.0789] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
37 Morizane C, Okusaka T, Morita S, Tanaka K, Ueno H, Kondo S, Ikeda M, Nakachi K, Mitsunaga S. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Pancreas. 2011;40:415-421. [PMID: 21283041 DOI: 10.1097/mpa.0b013e3182021376] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
38 Ouyang H, Wang P, Meng Z, Chen Z, Yu E, Jin H, Chang DZ, Liao Z, Cohen L, Liu L. Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine. Pancreas 2011;40:120-5. [PMID: 20683216 DOI: 10.1097/MPA.0b013e3181e6e398] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
39 Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. Cancer Res Treat 2016;48:1264-73. [PMID: 27034148 DOI: 10.4143/crt.2015.250] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
40 Kobayashi S, Ueno M, Irie K, Goda Y, Aoyama T, Morinaga S, Ohkawa S, Morimoto M. Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma. Pancreatology 2015;15:525-30. [PMID: 26255025 DOI: 10.1016/j.pan.2015.07.003] [Reference Citation Analysis]